Canagliflozin/metformin extended-release - Depomed/Janssen

Drug Profile

Canagliflozin/metformin extended-release - Depomed/Janssen

Alternative Names: CANA/MET XR FDC; Invokamet XR; Metformin extended-release/canagliflozin - Depomed/Janssen

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Depomed; Janssen Pharmaceutica
  • Class Antihyperglycaemics; Biguanides; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 13 Jul 2018 US FDA assigns PDUFA action date of 31/10/2018 for canagliflozin for the sNDA to reduce the risk of major adverse cardiovascular events in Type-2 diabetes mellitus
  • 13 Jul 2018 US FDA extends the review timeline for the sNDA to reduce the risk of major adverse cardiovascular events in Type 2 diabetes mellitus
  • 02 Oct 2017 Janssen Research and Development files sNDA to reduce the risk of major adverse cardiovascular events composed of cardiovascular death, myocardial infarction and stroke patients with Type 2 diabetes mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top